Opinion

Published within

« | ... | 1550 | 1551 | 1552 | 1553 | 1554 | 1555 | 1556 | 1557 | 1558 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

UBS: the Swiss are on a roll

UBS [UBS] has announced record profits for Q1 2004, driven by flourishing bond trading income and augmented fees from the group's wealth management businesses. As competition in the wealth management arena stiffens, UBS will need to develop a strong foothold outside Europe and the US to continue delivering exceptional performance to its shareholders.

Published By Datamonitor
05 May 2004
CommentWire
CommentWire

UBS: the unstoppable wealth machine

UBS' [UBS] purchase of Scott Goodman Harris, its second UK acquisition in two weeks, adds a further dimension to its UK high net worth offering. The purchase also enables the wealth manager to gain market share, experienced client managers and a lucrative client base in a relatively easy manner.

Published By Datamonitor
17 Feb 2004
CommentWire
CommentWire

UCB/Celltech: questions remain for CDP870

UCB's [UCB.BR] acquisition of Celltech [CLL] brings the Belgian company biotech expertise, while allowing Celltech's products to reach a wider market. However, the deal leaves doubts over whether UCB can market CDP870 in the valuable gastroenterology and rheumatoid arthritis markets to its maximum potential.

Published By Datamonitor
24 May 2004
CommentWire
CommentWire

UCB/Schwarz: a leading CNS proposition moves a step closer

The $5.5 billion takeover of Schwarz Pharma by Belgian rival UCB looks likely to go ahead, as preliminary figures show that UCB has received tenders in excess of 76% of the share capital of Schwarz Pharma. In addition to generating significant synergies, the deal is expected to create a leading neurology-focused pharmaceuticals group.

Published By Datamonitor
12 Dec 2006
CommentWire
CommentWire

UCB: allergy medication reveals increased sales

UCB's [UCB.BR] Zyrtec (cetrizine) sales are up 14% on the same quarter last year. The OTC and off-patent status of the leading antihistamine Claritin (loratadine) at the end of 2002 was expected to severely damage its competitor's sales. However, patients have instead rejected switching to readily available generic versions and have boosted prescription sales of Zyrtec.

Published By Datamonitor
26 Jan 2004
CommentWire
CommentWire

UCB: Cimzia approval suggests wider potential

Over two years after UCB initially filed Cimzia for Crohn's disease, the FDA has granted approval. Administered subcutaneously every four weeks, UCB's pegylated anti-TNFa offers a new treatment option for patients. The apparent persuasive powers of UCB bode well for the forecasted approval of Cimzia in the potentially more profitable indication of rheumatoid arthritis.

Published By Datamonitor
23 Apr 2008
CommentWire
CommentWire

UCB: Cimzia making good progress

A phase II clinical trial involving Cimzia, UCB and Nektar's anti-TNF alpha antibody, has demonstrated it to be effective and safe in treating psoriasis. However, despite this latest positive news, and Cimzia's advantages over other biologics, the drug candidate's anticipated late entry to the psoriasis drug market will have a negative impact upon its chances of success.

Published By Datamonitor
20 Jul 2006
CommentWire
CommentWire

UCB: Cimzia's indication expansion hindered by FDA

Although the FDA's complete response letter for Cimzia in rheumatoid arthritis will delay its US approval, Datamonitor believes UCB has the experience to handle the setback and the drug may still reach the market by the second half of 2009. Ultimately however, the delay will not be a major impediment as extensive uptake is not expected at launch due to poor differentiation in a mature drug class.

Published By Datamonitor
07 Jan 2009
CommentWire
CommentWire

UCB: continuing the European Mid-Pharma consolidation craze

Having enjoyed past success from acquisitions, Belgian-based UCB is now looking to Schwarz Pharma, with its impressive late-stage pipeline, to boost its growth potential. This merger agreement is the latest in a recent 'acquisition frenzy', and highlights the current trend towards consolidation in the European pharmaceutical sector.

Published By Datamonitor
26 Sep 2006
CommentWire
CommentWire

UCB: development of Keppra's successor makes headway

UCB has initiated a Phase III clinical program for brivaracetam as an adjunctive treatment in partial-onset epilepsy. Should it perform well here and gain marketing approval, the launch of this drug would serve to strengthen UCB's epilepsy franchise, as well as potentially representing an important treatment option for patients with refractory epilepsy.

Published By Datamonitor
26 Oct 2007

« | ... | 1550 | 1551 | 1552 | 1553 | 1554 | 1555 | 1556 | 1557 | 1558 | ... | » »|

No help is available.